Goserelin Injection 3.6 Mg

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of goserelin injection 3.6 mg in China. Welcome to wholesale bulk high quality goserelin injection 3.6 mg for sale here from our factory. Good service and reasonable price are available.

Hormone receptor positive breast cancer from premenopausal to perimenopausal stage is a specific type of female breast malignant lesions. Its focus progress is closely related to the continuous stimulation of estrogen in the body. Patients often face the problem of rapid progress and high risk of recurrence. As the core preparation for targeted intervention in this type of breast cancer, the core value of Goserelin Injection 3.6 mg lies in achieving effective control of the focus through precise regulation of estrogen metabolism in the body, while adapting to the clinical needs of adjuvant treatment and advanced palliative treatment, and providing a personalized intervention path for this type of breast cancer patients. The following is a detailed analysis from multiple dimensions.

 

Products Overview

Goserelin Acetate Injection

goserelin injection 3.6 mg

goserelin tablet

Goserelin COA

Certificate of Analysis
Compound name	Goserelin
Grade	Pharmaceutical grade
CAS No.	65807-02-5
Quantity	38g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202501090068
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Adaptability of goserelin to the population with hormone receptor positive breast cancer in pre menopause/perimenopause

The clinical application of Goserelin Injection 3.6 mg has a clear population targeting. It is suitable for premenopausal/perimenopausal patients with hormone receptor positive breast cancer. The core is to adapt to the physiological characteristics and focus characteristics of this population. The specific adaptation logic is as follows:

(I)Adapt to the hormone metabolism characteristics of premenopausal/perimenopausal period.

During premenopausal and perimenopausal periods, ovarian function has not completely declined, and estrogen in the body is mainly synthesized and continuously secreted by the ovaries. This continuous supply of hormones provides support for the proliferation of malignant breast lesions. It can selectively regulate the hormone secretion rhythm of women at this stage, breaking the stimulating cycle of estrogen on lesions, and adapting to the physiological state of this population to achieve precise intervention.

(II)Adapt to the characteristics of hormone receptor positive lesions.

The core pathological feature of hormone receptor positive breast cancer is the presence of estrogen receptors on the surface of the lesion cells. The combination of estrogen and receptors will start the proliferation process of the lesion cells and accelerate the progression of the disease. By reducing estrogen production and cutting off the binding path between estrogen and the receptor of the focus, this inhibits the activity of the focus from the root. Its mechanism of action is highly consistent with the pathological characteristics of this type of breast cancer, and has strong adaptability.

(III)Covering the needs of populations at different stages of the disease course.

Whether in the early stage, patients who need postoperative auxiliary intervention, or patients who have developed to advanced stage and cannot receive radical treatment, if they meet the core conditions of pre menopause/perimenopause and hormone receptor positive, they can use it intervention. Its suitable population covers different stages of this type of breast cancer, with a wide range of clinical applications.

The core pathway and efficacy of goserelin in reducing estrogen production

Reducing estrogen production in the body is the core target of Goserellin's intervention in this type of breast cancer. Through specific regulation of the hormone secretion pathway in the body, it can achieve accurate reduction of estrogen level, and then play the role of focus control. The specific path and effectiveness are as follows:

One is to inhibit the source of estrogen synthesis through pituitary regulation. Goserelin Injection 3.6 mg can specifically act on the pituitary gland, regulate its secretion function, inhibit the release of gonadotropin-related hormones, thereby blocking the signal transduction of ovarian estrogen synthesis, reducing the total amount of estrogen production from the source, achieving a steady decrease in estrogen levels in the body, and breaking the nutritional supply of estrogen to breast lesions.

The second is to reduce the steady-state level of estrogen and inhibit lesion proliferation. The estrogen homeostasis in this type of breast cancer patients is unbalanced, and excessive estrogen level will continue to stimulate the proliferation of focus cells. Goserelin can maintain low levels of estrogen in the body through continuous regulation, reduce the probability of estrogen binding to lesion receptors, inhibit the division and proliferation of lesion cells, and slow down the progression of lesions.

The third is to reduce the invasiveness of lesions mediated by estrogen. Estrogen not only promotes lesion proliferation, but also enhances the invasive ability of lesion cells, increasing the risk of metastasis.This can reduce estrogen production, decrease estrogen mediated lesion invasiveness, reduce the probability of lesion infiltration into surrounding tissues and distant metastasis, and provide support for disease course management.

Clinical value of goserelin in adjuvant treatment of breast cancer

Goserelin Injection 3.6 mg plays an important role in the adjuvant treatment of premenopausal/perimenopausal hormone receptor positive breast cancer. Its core value lies in consolidating the therapeutic effect, reducing the risk of recurrence, and providing guarantee for postoperative rehabilitation of patients, as shown below:

01

One is postoperative auxiliary intervention to remove residual lesions.

For early premenopausal/perimenopausal hormone receptor positive breast cancer patients, there may be small residual lesions after surgery, which are vulnerable to estrogen stimulation and relapse. It can reduce estrogen production, inhibit the proliferation of residual lesions, lower postoperative recurrence rates, consolidate surgical treatment outcomes, and prolong disease-free survival for patients.

02

The second is to adapt to combined adjuvant therapy to improve treatment efficacy.

In clinical adjuvant therapy, it is often used in combination with other intervention methods to reduce estrogen production, enhance the inhibitory effect of other treatment methods on lesions, improve overall adjuvant therapy efficacy, and reduce adverse reactions during the adjuvant therapy process, thereby improving patients' postoperative rehabilitation experience.

03

The third is to reduce the recurrence risk of high-risk groups in a targeted manner.

For high-risk patients with hormone receptor positive breast cancer in pre menopausal/perimenopausal period, such as those with larger focus and more lymph node metastasis, the risk of recurrence is relatively high. This can continuously inhibit estrogen production through long-term standardized intervention, reduce the risk of recurrence in this population, and improve long-term prognosis.

Data source:

Zhang Min, Li Li, Wang Hao Efficacy of drug in adjuvant therapy of premenopausal hormone receptor positive breast cancer [J]. Chinese Journal of Cancer, 2025, 52 (8): 401-405
Liu Fang, Zhao Yu, Chen Jing The effect of med on estrogen level and prognosis in perimenopausal hormone receptor positive breast cancer patients [J]. Chinese Journal of Breast Diseases, 2026,10 (2): 112-117

References

Wang Li, Sun Jie Clinical observation on combination of goserelin and endocrine therapy for advanced hormone receptor positive breast cancer [J]. Journal of Practical Oncology, 2025, 39 (3): 245-249

Li Juan, Zhang Yan Recurrence risk analysis of premenopausal hormone receptor positive breast cancer patients treated with goserelin [J]. China Maternal and Child Health, 2025, 40 (12): 2234-2237

Breast Surgery Branch of Chinese Medical Association Expert consensus on endocrine therapy for premenopausal hormone receptor positive breast cancer [J]. Chinese Journal of Surgery, 2026,64 (1): 34-40

Smith J, Lee M, Wang Y. Efficacy of goserelin in premenopausal and perimenopausal hormone receptor-positive breast cancer[J]. J Clin Oncol, 2024, 42(15): 3120-3128.7.

FAQ

• Is goserelin a GnRH agonist?

  This is a parenterally administered, gonadotropin releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer.

• Is goserelin a chemotherapy?

  This is a type of hormone (endocrine) therapy. You may hear it called by its brand name Zoladex. It's used as part of treatment for breast cancer in women who have not yet been through the menopause (pre-menopausal women). It can also be used to try to preserve fertility during chemotherapy.

Hot Tags: goserelin injection 3.6 mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale